Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.

MLA

Park, Ji Hyun, et al. “Hyperprogressive Disease and Its Clinical Impact in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Immune-Checkpoint Inhibitors: Korean Cancer Study Group HN 18-12.” Journal of Cancer Research and Clinical Oncology, vol. 146, no. 12, Dec. 2020, pp. 3359–69. EBSCOhost, https://doi.org/10.1007/s00432-020-03316-5.

APA

Park, J. H., Chun, S. H., Lee, Y.-G., Chang, H., Lee, K.-W., Kim, H. R., Shin, S. H., An, H. J., Lee, K. E., Hwang, I. G., Ahn, M.-J., Kim, S.-B., & Keam, B. (2020). Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. Journal of Cancer Research and Clinical Oncology, 146(12), 3359–3369. https://doi.org/10.1007/s00432-020-03316-5

Chicago

Park, Ji Hyun, Sang Hoon Chun, Yun-Gyoo Lee, Hyun Chang, Keun-Wook Lee, Hye Ryun Kim, Seong Hoon Shin, et al. 2020. “Hyperprogressive Disease and Its Clinical Impact in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Immune-Checkpoint Inhibitors: Korean Cancer Study Group HN 18-12.” Journal of Cancer Research and Clinical Oncology 146 (12): 3359–69. doi:10.1007/s00432-020-03316-5.